Wu et al. investigated the efficacy and safety of fruquintinib plus sintilimab in 34 Chinese patients with advanced cervical cancer. The study finds that 32% of patients responded to the combination treatment and disease was controlled in 97%; side effects were manageable.
- Xiaohua Wu
- Danbo Wang
- Weiguo Su
